Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
CD40 Targeted Therapies Clinical Trials & Market
CD40 targeted therapies in immunotherapy research focus on the CD40 receptor for treating various diseases, with no approvals yet but promising candidates in late-stage clinical development. First approval expected by 2027, with over 20 therapies in trials. Interest in CD40 targeting expands to cancer, infectious diseases, and neurodegenerative diseases. Antibody therapies dominate, with advanced candidates like Sanofi's Frexalimab and Alligator Bioscience's mitazalimab. Proprietary technologies like GenMab's DuoBody platform facilitate development. Major pharmaceutical companies like Amgen, Sanofi, and GenMab are key players, with collaborations advancing research.
Epilepsy Drugs Market to Surpass $9.8 Billion by 2032: FDA Approval of UCB's VIMPAT
The global epilepsy drugs market, valued at $7 billion in 2022, is projected to reach $9.8 billion by 2032, driven by increasing prevalence and advancements in treatment options. Key players include Novartis AG, GlaxoSmithKline plc, Sanofi, Abbott Laboratories, and UCB S.A., focusing on product approvals and innovations.
Positive phase III data in IPT
Sanofi presents positive phase III results for rilzabrutinib in treating persistent or chronic ITP at ASH annual meeting, showing rapid and durable platelet response, reduced bleeding, and improved quality of life.
Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia
Rilzabrutinib, an oral BTK inhibitor, demonstrated safety and efficacy in boosting platelet counts in heavily pretreated ITP patients, achieving a durable platelet response in 23% vs. 0% placebo at week 25. The study met secondary endpoints, showing reduced fatigue, rescue medication use, and bleeding events. Rilzabrutinib may offer a safer treatment option for ITP compared to first-generation BTK inhibitors.
Oncology Market Overview and Leading Players: Daiichi Sankyo
The Oncology Market is critical in global healthcare, driven by cancer prevalence, technological advancements, and strategic collaborations. Key players like Daiichi Sankyo, Bayer AG, and others innovate in diagnostics, treatments, and precision medicine. Market growth is fueled by R&D investments, sustainability focus, and consumer awareness. Challenges include regulatory constraints and talent shortages. Technological integrations like AI and IoT enhance patient care and operational efficiency.
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by
The mRNA Therapeutics Market was valued at USD 11.82 billion in 2023 and is projected to reach USD 48.65 billion by 2032, with a CAGR of 17.04%. The market's growth is driven by mRNA-based vaccines against COVID-19, advancements in mRNA-based cancer therapies, and regulatory approvals. North America leads the market, followed by Europe, while Asia Pacific is expected to grow the fastest.
Sanofi advances a drug for a rare, platelet-destroying disease
Sanofi's rilzabrutinib shows promise in treating immune thrombocytopenia, while Novo Nordisk's etavopivat reduces sickle cell pain crises. Beam Therapeutics' CRISPR therapy for sickle cell yields consistent results, though fertility preservation remains a concern.
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive ...
Rilzabrutinib, a BTK inhibitor, showed significant efficacy in ITP patients, with 65% achieving platelet response vs. 33% on placebo. The study met primary and secondary endpoints, including durable platelet response, reduced bleeding, and improved quality of life. Rilzabrutinib is under regulatory review in the US and EU.
© Copyright 2024. All Rights Reserved by MedPath